P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 98, Issue 1, 2001, Pages 103-108

  Coronado, Pluvio J ^a   Vidart, Jose A ^a   Lopez asenjo, Jose A ^a   Fasero, Maria ^a   Furio bacete, Vicente ^a   Magrina, Javier ^b   Escudero, Manuel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b MAYO CLINIC   (United States)

Author keywords

Endometrial cancer; HER 2 neu; Immunohistochemistry; p53; Prognostic factors; Survival

Indexed keywords

PARAFFIN; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CORRELATION FUNCTION; DIFFERENTIATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0034865669     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00562-5     Document Type: Article

References (38)

1. Endometrial hyperplasia and endometrial cancer
2. The prognostic significance of surgical staging for carcinoma of the endometrium
3. Risk factor and recurrence patterns in stage I endometrial cancer
4. Carcinoma of the endometrium: Effect of stage and grade on survival
5. Prognostic factors in early carcinoma of endometrium
6. Peritoneal cytology in patients with endometrial carcinoma
7. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma
8. Tumor suppresor genes
9. The p53 tumor supressor gene
10. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma
11. Prognostic significance of p53 overexpression in endometrial cancer
12. Prognostic significance of p53, bcl-2, vimentin and S100 protein-positive Langerhans cells in endometrial carcinoma
13. The neu oncogene encodes an epidermal growth factor receptor-related protein
14. Endometrial carcinoma: Inmunohistochemically detected proliferation index is a prognosticator of long term outcome
15. Non parametric stimation from incomplete observation
16. Regression models and life-tables
17. Overexpression and mutation of p53 in endometrial carcinoma
18. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer
19. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53
20. Clinicopathological characteristics of p53 overexpression in endometrial cancers
21. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression
22. Loss of p53 function in uterine papillary serous carcinoma
23. Proliferative and apoptotic status in endometrial adenocarcinoma
24. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma
25. Immunohistochemical analysis of p53 protein overexpression in endometrial carcinomas: Inverse correlation with sex steroid receptor status
26. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras 2 protooncogene in premalignant and lesion of the human uterine endometrium
27. p53 Protein overexpression in early stage endometrial cancer
28. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
29. p53 Protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma
30. HER-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma
31. Expressions of p53, transforming growth factor alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
32. Multivariable analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial cancer
33. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
34. Expression of EGFR, HER-2/neu, p53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas
35. Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas
36. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor and steroid receptor expression in normal and malignant endometrium
37. HER-2/neu expression: A major prognostic factor in endometrial cancer
38. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer